(4S)-4-[[叔丁氧羰基]氨基]-5-[(2,5-二氧代-1-吡咯烷基)氧基]-5-氧代戊酸叔丁酯 | 32886-55-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - BOC-氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (4S)-4-[[叔丁氧羰基]氨基]-5-[(2,5-二氧代-1-吡咯烷基)氧基]-5-氧代戊酸叔丁酯
• 中文别名: 苄氧羰基-5-叔丁酯-L-谷氨酸琥珀酰亚胺酯
• 英文名称: (S)-5-tert-butyl 1-(2,5-dioxopyrrolidin-1-yl) 2-((tert-butoxycarbonyl)amino)pentanedioate
• 英文别名: Boc-Glu(OtBu)-OSu；5-O-tert-butyl 1-O-(2,5-dioxopyrrolidin-1-yl) (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioate
• CAS: 32886-55-8
• 化学式: C₁₈H₂₈N₂O₈
• 分子量: 400.429
• InChiKey: HZDCTRJVURFFQX-NSHDSACASA-N

物化性质

• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  8

安全信息

• 储存条件：
  室温、密封、干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-glu(otbu)-osu
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-glu(otbu)-osu
CAS number: 32886-55-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C18H28N2O8
Molecular weight: 400.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4S)-4-[[叔丁氧羰基]氨基]-5-[(2,5-二氧代-1-吡咯烷基)氧基]-5-氧代戊酸叔丁酯 在 palladium on activated charcoal N-甲基吗啉 、 1-氯-N,N,2-三甲基丙烯胺 、 氢气 、 N,N-二异丙基乙胺 、 三氟乙酸 、 氯甲酸异丁酯 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， -15.0~25.0 ℃ 、101.33 kPa 条件下， 反应 54.75h， 生成 (4S)-5-[[(2S)-3-[4-[6-[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-6-oxohexanoyl]oxyphenyl]-1-[[(2S)-4-methyl-1-morpholin-4-yl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-azaniumyl-5-oxopentanoate
  参考文献：
  名称：

  合成的三肽和四肽作为表皮生长因子受体蛋白酪氨酸激酶的潜在双底物抑制剂

  摘要：

  描述了一系列的表皮生长因子受体蛋白激酶（EGF-R PTK）的双底物抑制剂的合成，这些抑制剂由通过适当的三磷酸酯替代物与腺苷共价连接的小肽组成。Boc-Glu（O t Bu）-Tyr-Leu-OBzl（5）和Ac-Glu（O t Bu）-Tyr-Leu-Arg（Pmc）-NH 2（8 ; Pmc = 2,2,5,7通过标准的肽化学制备（8-五甲基苯并吡喃-6-磺酰基）（方案1），然后用己二酸酐或4-（氯磺酰基）苯甲酸，4-（氯磺酰基）-2在酪氨酸的OH基上进行修饰。 -羟基苯甲酸或苯-1,4-二磺酰二氯（方案2），最后与2'，3'- O-异丙基亚氨腺苷的5'-OH基偶联（方案3）。另外，将ATP替代物N 6 -[（苄氧基）羰基] -2'，3' - O-异亚丙基-腺苷5'-（己二酸氢二乙酯）（26）与5的吗啉化物偶联（方案4）。除去保护基得到双底物类似物23、24和28。测试了合成的化合物作为EGF-R

  DOI：

  10.1002/hlca.19970800304
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 叔丁氧羰基-L-谷氨酸-5-叔丁酯 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 (4S)-4-[[叔丁氧羰基]氨基]-5-[(2,5-二氧代-1-吡咯烷基)氧基]-5-氧代戊酸叔丁酯
  参考文献：
  名称：

  具有可调电荷反转特性的氨肽酶 N 反应性偶联物，可实现高效的肿瘤积累和穿透

  摘要：

  合成了具有可调电荷反转率的氨肽酶 N (APN) 响应电荷反转聚合物-药物偶联物。单体单元结构（酰胺的 α- 取代基）和聚合物链结构决定了酶促水解和电荷反转率，并因此决定了 APN 反应性缀合物的转胞吞作用和肿瘤积累和渗透。具有中等APN反应性的缀合物平衡了体外和体内递送效率并取得最佳抗肿瘤功效。

  DOI：

  10.1002/anie.202217408

文献信息

• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• [EN] ANTI-EGFR ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉ ANTICORPS-MÉDICAMENT ANTI-EGFR
  申请人：ABBVIE INC

  公开号：WO2017214282A1

  公开（公告）日：2017-12-14

  The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs. Formula (IIa), (IIb), (IIc)

  本发明涉及抑制Bcl-xL的抗表皮生长因子受体（EGFR）抗体药物偶联物（ADCs），包括所述ADCs的组成和方法。公式（IIa），（IIb），（IIc）
• Ynamide-Mediated Thiopeptide Synthesis
  作者：Jinhua Yang、Changliu Wang、Silin Xu、Junfeng Zhao

  DOI：10.1002/anie.201811586

  日期：2019.1.28

  two‐step strategy for thiopeptide bond formation with readily available monothiocarboxylic acids as thioacyl donors is described. The α‐thioacyloxyenamide intermediates formed from the ynamides and monothiocarboxylic acids can be purified, characterized, and stored. The balance between their activity and stability enables them to act as effective thioacylating reagents to afford thiopeptide bonds under mild

  不足的合成策略不足以将硫酰胺键位点引入肽主链，因此无法探索作为肽和蛋白质化学生物学工具的硫酰胺替代物的全部潜力。描述了一种新颖的由酰胺介导的两步策略，用于以易于获得的单硫代羧酸作为硫代酰基供体的硫肽键形成。由乙酰胺和一硫代羧酸形成的α-硫代酰氧烯酰胺中间体可以进行纯化，表征和储存。它们的活性和稳定性之间的平衡使它们能够充当有效的硫酰化试剂，在温和的反应条件下提供硫肽键。氨基酸官能团，例如OH，CONH 2，并且在巯基肽合成过程中不需要保护吲哚NH基团。这种策略的模块化性质使得在溶液和固相中都可以将硫酰胺键定点结合到肽主链中。
• [EN] BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME<br/>[FR] COMPOSÉS INHIBITEURS DE BCL XL AYANT UNE FAIBLE PERMÉABILITÉ CELLULAIRE ET CONJUGUÉS ANTICORPS-MÉDICAMENT COMPRENANT CEUX-CI
  申请人：ABBVIE INC

  公开号：WO2016094509A1

  公开（公告）日：2016-06-16

  The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

  本公开涉及具有低细胞渗透性的Bcl-xL抑制剂，包括这些抑制剂的抗体药物结合物（ADCs），用于合成ADCs的合成子，包括这些抑制剂或ADCs的组合物，以及使用这些抑制剂和ADCs的各种方法。
• METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE
  申请人：Waterville Valley Technologies, Inc.

  公开号：US20160326182A1

  公开（公告）日：2016-11-10

  Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.

  提供了耐滥用的阿片类化合物、药物输送系统、含有阿片类药物与化学基团共价结合的制药组合物。还提供了将活性成分输送给受试者的方法以及预防阿片类药物滥用的方法。